Advertisement

Topics

FibroGen Announces Completion of Enrollment in U.S. Phase 3 Clinical Program for Roxadustat

11:33 EDT 7 Jun 2018 | Investing News Network

FibroGen (NASDAQ:FGEN), a biopharmaceutical company, today announced the completion of patient enrollment in the Phase 3 studies supporting the U.S. new drug application (NDA) submission for roxadustat in anemia associated with chronic kidney disease (CKD). The Phase 3 clinical program is evaluating the use of roxadustat for the treatment of anemia in both dialysis-dependent and non-dialysis-dependent … Continued

The post FibroGen Announces Completion of Enrollment in U.S. Phase 3 Clinical Program for Roxadustat appeared first on Investing News Network.

Original Article: FibroGen Announces Completion of Enrollment in U.S. Phase 3 Clinical Program for Roxadustat

NEXT ARTICLE

More From BioPortfolio on "FibroGen Announces Completion of Enrollment in U.S. Phase 3 Clinical Program for Roxadustat"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...